These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19585083)

  • 1. A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer.
    Shin SJ; Jeung HC; Ahn JB; Rha SY; Roh JK; Park KS; Kim DH; Kim C; Chung HC
    Invest New Drugs; 2010 Oct; 28(5):650-8. PubMed ID: 19585083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
    Shin SJ; Ahn JB; Park KS; Lee YJ; Hong YS; Kim TW; Kim HR; Rha SY; Roh JK; Kim DH; Kim C; Chung HC
    Invest New Drugs; 2012 Apr; 30(2):672-80. PubMed ID: 21188464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, distribution, metabolism, and excretion of CKD-732, a novel antiangiogenic fumagillin derivative, in rats, mice, and dogs.
    Lee HS; Choi WK; Son HJ; Lee SS; Kim JK; Ahn SK; Hong CI; Min HK; Kim M; Myung SW
    Arch Pharm Res; 2004 Feb; 27(2):265-72. PubMed ID: 15029870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin.
    Kim JH; Lee SK; Ki MH; Choi WK; Ahn SK; Shin HJ; Hong CI
    Int J Pharm; 2004 Mar; 272(1-2):79-89. PubMed ID: 15019071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
    Jonker DJ; Rosen LS; Sawyer MB; de Braud F; Wilding G; Sweeney CJ; Jayson GC; McArthur GA; Rustin G; Goss G; Kantor J; Velasquez L; Syed S; Mokliatchouk O; Feltquate DM; Kollia G; Nuyten DSA; Galbraith S
    Ann Oncol; 2011 Jun; 22(6):1413-1419. PubMed ID: 21131369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled trial of beloranib for the treatment of hypothalamic injury-associated obesity.
    Shoemaker A; Proietto J; Abuzzahab MJ; Markovic T; Malloy J; Kim DD
    Diabetes Obes Metab; 2017 Aug; 19(8):1165-1170. PubMed ID: 28261955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
    Lockhart AC; Rothenberg ML; Dupont J; Cooper W; Chevalier P; Sternas L; Buzenet G; Koehler E; Sosman JA; Schwartz LH; Gultekin DH; Koutcher JA; Donnelly EF; Andal R; Dancy I; Spriggs DR; Tew WP
    J Clin Oncol; 2010 Jan; 28(2):207-14. PubMed ID: 19949018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
    Spratlin JL; Cohen RB; Eadens M; Gore L; Camidge DR; Diab S; Leong S; O'Bryant C; Chow LQ; Serkova NJ; Meropol NJ; Lewis NL; Chiorean EG; Fox F; Youssoufian H; Rowinsky EK; Eckhardt SG
    J Clin Oncol; 2010 Feb; 28(5):780-7. PubMed ID: 20048182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
    McCandless SE; Yanovski JA; Miller J; Fu C; Bird LM; Salehi P; Chan CL; Stafford D; Abuzzahab MJ; Viskochil D; Barlow SE; Angulo M; Myers SE; Whitman BY; Styne D; Roof E; Dykens EM; Scheimann AO; Malloy J; Zhuang D; Taylor K; Hughes TE; Kim DD; Butler MG
    Diabetes Obes Metab; 2017 Dec; 19(12):1751-1761. PubMed ID: 28556449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors.
    Farrell PJ; Zopf CJ; Huang HJ; Balakrishna D; Holub C; Bilakovics J; Fanjul A; Matuszkiewicz J; Plonowski A; Rolzin P; Banerjee U; Ermolieff J; Cheruvallath ZS; McBride C; Bartkowski D; Mazur C; Pachori A; Larson CJ
    J Pharmacol Exp Ther; 2019 Nov; 371(2):299-308. PubMed ID: 31537613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732.
    Kim YM; An JJ; Jin YJ; Rhee Y; Cha BS; Lee HC; Lim SK
    J Mol Endocrinol; 2007 Apr; 38(4):455-65. PubMed ID: 17446235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
    Rugo HS; Herbst RS; Liu G; Park JW; Kies MS; Steinfeldt HM; Pithavala YK; Reich SD; Freddo JL; Wilding G
    J Clin Oncol; 2005 Aug; 23(24):5474-83. PubMed ID: 16027439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.
    Eskens FA; Ramos FJ; Burger H; O'Brien JP; Piera A; de Jonge MJ; Mizui Y; Wiemer EA; Carreras MJ; Baselga J; Tabernero J
    Clin Cancer Res; 2013 Nov; 19(22):6296-304. PubMed ID: 23983259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Rizvi N; Dahut W; Yoe J; Figuera M; Phipps K; Ong VS; Kato A; Hawkins MJ
    Clin Cancer Res; 1999 Aug; 5(8):1989-95. PubMed ID: 10473076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
    Herbst RS; Madden TL; Tran HT; Blumenschein GR; Meyers CA; Seabrooke LF; Khuri FR; Puduvalli VK; Allgood V; Fritsche HA; Hinton L; Newman RA; Crane EA; Fossella FV; Dordal M; Goodin T; Hong WK
    J Clin Oncol; 2002 Nov; 20(22):4440-7. PubMed ID: 12431966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.
    Tew WP; Gordon M; Murren J; Dupont J; Pezzulli S; Aghajanian C; Sabbatini P; Mendelson D; Schwartz L; Gettinger S; Psyrri A; Cedarbaum JM; Spriggs DR
    Clin Cancer Res; 2010 Jan; 16(1):358-66. PubMed ID: 20028764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of recombinant human endostatin in patients with advanced solid tumors.
    Herbst RS; Hess KR; Tran HT; Tseng JE; Mullani NA; Charnsangavej C; Madden T; Davis DW; McConkey DJ; O'Reilly MS; Ellis LM; Pluda J; Hong WK; Abbruzzese JL
    J Clin Oncol; 2002 Sep; 20(18):3792-803. PubMed ID: 12228199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system.
    Kim EJ; Shin WH
    Biol Pharm Bull; 2005 Feb; 28(2):217-23. PubMed ID: 15684472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.
    Glade Bender JL; Adamson PC; Reid JM; Xu L; Baruchel S; Shaked Y; Kerbel RS; Cooney-Qualter EM; Stempak D; Chen HX; Nelson MD; Krailo MD; Ingle AM; Blaney SM; Kandel JJ; Yamashiro DJ;
    J Clin Oncol; 2008 Jan; 26(3):399-405. PubMed ID: 18202416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.